UroGen Pharma Ownership | Who Owns UroGen Pharma?
UroGen Pharma Ownership Summary
UroGen Pharma is owned by 81.50% institutional investors, 9.18% insiders, and 9.32% retail investors. Rtw investments, lp is the largest institutional shareholder, holding 10.66% of URGN shares. UBS (Lux) Digital Health Equity SB USD is the top mutual fund, with 3.13% of its assets in UroGen Pharma shares.
URGN Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | UroGen Pharma | 81.50% | 9.18% | 9.32% |
Sector | Healthcare Stocks | 47.06% | 8.01% | 44.93% |
Industry | Biotech Stocks | 44.97% | 7.82% | 47.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Rtw investments, lp | 3.56M | 10.66% | $59.69M |
Adage capital partners gp | 3.30M | 9.89% | $55.37M |
Great point partners | 2.91M | 8.71% | $48.77M |
Point72 asset management | 2.45M | 7.34% | $41.10M |
Menora mivtachim | 2.30M | 6.90% | $38.64M |
Blackrock | 2.19M | 6.57% | $36.81M |
Cowen and company | 2.10M | 6.29% | $35.23M |
Morgan stanley | 1.84M | 5.51% | $30.85M |
Cormorant asset management, lp | 1.65M | 4.94% | $27.69M |
Ubs asset management americas | 1.32M | 3.95% | $22.15M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Great point partners | 2.91M | 9.34% | $48.77M |
Silverarc capital management | 1.10M | 4.36% | $18.49M |
Wildcat capital management | 495.61K | 2.04% | $8.32M |
Dafna capital management | 469.00K | 1.88% | $7.87M |
Cormorant asset management, lp | 1.65M | 1.60% | $27.69M |
Opaleye management | 412.00K | 1.58% | $6.91M |
Cowen and company | 2.10M | 0.97% | $35.23M |
Rtw investments, lp | 3.56M | 0.92% | $59.69M |
Parkman healthcare partners | 274.46K | 0.62% | $4.61M |
De lisle partners llp | 81.51K | 0.30% | $1.37M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Adage capital partners gp | 3.30M | 0.10% | 2.00M |
Cormorant asset management, lp | 1.65M | 1.60% | 1.65M |
Morgan stanley | 1.84M | 0.00% | 1.45M |
Point72 asset management | 2.45M | 0.11% | 1.34M |
Ubs asset management americas | 1.32M | 0.01% | 1.32M |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Ra capital management | - | - | -3.08M |
Superstring capital management lp | - | - | -288.27K |
Price t rowe associates inc /md/ | 10.95K | - | -256.19K |
Harel insurance investments & financial services | 463.56K | 0.15% | -209.92K |
Laurion capital management lp | - | - | -160.60K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Cormorant asset management, lp | 1.65M | 1.60% | 1.65M | $27.69M |
Ubs asset management americas | 1.32M | 0.01% | 1.32M | $22.15M |
Dafna capital management | 469.00K | 1.88% | 469.00K | $7.87M |
Woodline partners lp | 303.74K | 0.05% | 303.74K | $5.10M |
Trexquant investment lp | 80.71K | 0.02% | 80.71K | $1.35M |
Sold Out
Holder | Change |
---|---|
Nelson, van denburg & campbell wealth management group | -4.00 |
Toronto dominion bank | -6.00 |
Systm wealth solutions | -48.00 |
Eversource wealth advisors | -57.00 |
Lindbrook capital | -87.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Sep 30, 2024 | 132 | 9.09% | 35,128,434 | -8.10% | 81 | 0.76% | 75 | -5.06% | 30 | 50.00% |
Jun 30, 2024 | 120 | 2.56% | 38,225,515 | 40.73% | 114 | 2.03% | 78 | 56.00% | 20 | -45.95% |
Mar 31, 2024 | 117 | 8.33% | 27,162,135 | 26.89% | 75 | 1.71% | 50 | -24.24% | 37 | 85.00% |
Dec 31, 2023 | 108 | 1.89% | 21,406,800 | 20.71% | 66 | 1.16% | 66 | 6.45% | 20 | -9.09% |
Sep 30, 2023 | 106 | 19.10% | 17,734,025 | 34.25% | 75 | 2.35% | 62 | 34.78% | 22 | 10.00% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
UBS (Lux) Digital Health Equity SB USD | 1.32M | 3.13% | - |
iShares Russell 2000 ETF | 957.94K | 2.27% | -2.16K |
Fidelity Small Cap Index | 351.12K | 0.83% | -9.33K |
MEDICAL BioHealth EUR Acc | 294.71K | 0.70% | -238.32K |
iShares Biotechnology ETF | 269.09K | 0.64% | -1.61K |
State St Russell Sm/Mid Cp® Indx NL Cl C | 262.40K | 0.62% | - |
iShares Russell 2000 Growth ETF | 258.82K | 0.61% | - |
Vanguard Russell 2000 ETF | 172.12K | 0.41% | -1.09K |
ARK Israel Innovative Technology ETF | 161.86K | 0.38% | - |
SPDR® Portfolio Developed Wld ex-US ETF | 120.41K | 0.29% | - |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Sep 09, 2024 | Schoenberg Mark | Chief Medical Officer | Sell | $11.24K |
Sep 09, 2024 | Smith Jason Drew | General Counsel | Sell | $19.89K |
Jun 10, 2024 | Schoenberg Mark | Chief Medical Officer | Sell | $67.40K |
Mar 18, 2024 | Schoenberg Mark | Chief Medical Officer | Sell | $168.60K |
Feb 01, 2024 | Smith Jason Drew | General Counsel | Sell | $52.52K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2024 Q4 | - | - |
2024 Q3 | - | 2 |
2024 Q2 | - | 1 |
2024 Q1 | - | 13 |
2023 Q3 | - | 1 |
URGN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools